Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ulviprubart, an antibody targeting KLRG1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Simaravibart, an antibody targeting SARS-CoV-2 Spike RBD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sabirnetug, an antibody targeting Amyloid-beta.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Raludotatug, an antibody targeting CDH6.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vecantoxatug, an antibody targeting Clostridium tetani tetanus toxin (TeNT).

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tizetatug, an antibody targeting TROP2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Telikibart, an antibody targeting IL-4Ralpha.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tabirafusp, an antibody targeting IL6.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Surovatamig, an antibody targeting CD3D&CD3E × CD19.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sonesitatug, an antibody targeting Claudin 18.2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Omectatug, an antibody targeting Claudin 18.2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Gulgafafusp, an antibody targeting GLP1R.